VIVEVE MED INC
VIVE
VIVE was delisted on the 18th of January, 2023.
1 hedge funds and large institutions have $1.57K invested in VIVEVE MED INC in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 16 closing their positions.
94% less funds holding
Funds holding: 16 → 1 (-15)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 16
99% less capital invested
Capital invested by funds: $216K → $1.57K (-$214K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$104K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$25.6K |
| 3 |
State Street
Boston,
Massachusetts
|
-$23.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$21K |
| 5 |
Renaissance Technologies
New York
|
-$14K |
VIVE Hedge Fund Activity: Q1 2023 in Review
1 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in VIVEVE MED INC (VIVE) for Q1 2023, worth a combined $1.57K — down 99% from $216K a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VIVE and 1 opened new positions — a net loss of 15 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $17K. The largest seller was BlackRock, exiting entirely with an estimated $104K sold.
- 1 institutional investor held VIVEVE MED INC (VIVE) as of Q1 2023, down from 16 in Q4 2022.
- Funds reported $1.57K of VIVEVE MED INC stock for Q1 2023, down 99% quarter-over-quarter.
- 1 fund opened new VIVEVE MED INC positions in Q1 2023 and 16 closed out, a net change of -15 holders.
- The largest VIVEVE MED INC buyer in Q1 2023 was Cantor Fitzgerald, an estimated $17K added.
- The largest VIVEVE MED INC seller in Q1 2023 was BlackRock, an estimated $104K sold.
Based on aggregated 13F filings for Q1 2023.